HilleVax, Inc.
NASDAQ:HLVX
Overview | Financials
Company Name | HilleVax, Inc. |
Symbol | HLVX |
Currency | USD |
Price | 1.87 |
Market Cap | 93,137,351 |
Dividend Yield | 0% |
52-week-range | 1.55 - 20.22 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Robert M. Hershberg M.D., Ph.D. |
Website | https://www.hillevax.com |
An error occurred while fetching data.
About HilleVax, Inc.
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD